avagacestat + galantamine

Avagacestat + galantamine is a combination of two investigational and approved drugs developed as a potential therapy for Alzheimer’s disease and related cognitive disorders. **Avagacestat** is an oral small molecule γ-secretase inhibitor designed to selectively inhibit amyloid-β (Aβ) synthesis, reducing amyloid plaque formation implicated in Alzheimer’s disease pathology[3]. By selectively targeting γ-secretase, avagacestat aims to reduce Aβ production without notably inhibiting cleavage of Notch substrates, minimizing associated toxicities[3]. **Galantamine** is a small molecule acetylcholinesterase inhibitor and a positive allosteric modulator of nicotinic acetylcholine receptors, enhancing cholinergic neurotransmission and modulating synaptic activity[2][1]. The rationale for combining these drugs is to synergistically target both amyloid pathology (through avagacestat) and cholinergic deficits (through galantamine), potentially providing greater cognitive benefits than monotherapy. Both act via distinct but complementary mechanisms: avagacestat reduces amyloid generation while galantamine augments neurotransmitter activity and nicotinic receptor function.

Brand names

Razadyne (for galantamine)